Abstract: A cathode material featuring PVM for use in rechargeable electrochemical cells. It has been discovered that the polymer backbone of PVM, which consists solely of carbon atoms, is not subject to scission during repeated charge-discharge cycles, such that the cathode material remains substantially insoluble in standard liquid electrolytes. As a result, cells containing PVM as the cathode material and liquid electrolyte are genuinely electrochemically reversible. The use of PVM overcomes the problems associated with organosulfides of the background art, with which dissolution of anions in the liquid electrolyte during discharging results in migration from the cathode and contamination of the anode/electrolyte surface and ultimately leads to degradation of the electrolyte and/or deterioration of the anode-electrolyte interface.

Abstract: A method and a measuring device for determining the spatial distribution of a magnetic field vector. At least a pair of sensor elements is provided. Each sensor element measures a component of the magnetic field vector. The sensor elements are aligned in a parallel, spaced-apart relationship along an axis parallel to the measured components.

Abstract: Disclosed are compounds of the following formulae, and their use in the polymerization of olefins: wherein M is preferably titanium, zirconium or hafnium, R1-R8 are univalent radicals, X1 and X2 are univalent ligands, X3 is a divalent ligand, and (RnY—T) is an optional donor or non-donor group.

Abstract: The present invention provides a method for treating a viral infection in a subject. The method comprises administering to the subject an amount of 5-aminolevulinic acid to cause virus-infected cells to accumulate protoporphyrin in amounts such that upon application of a sufficient dose of red light, the virus-infected, protoporphyrin-accumulated cells will be destroyed; and applying a sufficient dose of red light to the virus-infected, protoporphyrin-accumulated cells to destroy the virus-infected, protoporphyrin-accumulated cells.

Abstract: A non-aqueous electrolyte for use in an electrochemical cell comprising: (a) at least one organic solvent; (b) at least one electrolytically active salt represented by the formula: M′+m(ZRnXq−n)m in which: M′ is selected from a group consisting of magnesium, calcium, aluminum, lithium and sodium; Z is selected from a group consisting of aluminum, boron, phosphorus, antimony and arsenic; R represents radical selected from the following groups: alkyl, alkenyl, aryl, phenyl, benzyl, and amido; X is a halogen (I, Br, Cl, F); m=1-3; and n=0-5 and q=6 in the case of Z=phosphorus, antimony and arsenic, and n=0-3 and q=4 in the case of Z=aluminum and boron. Rechargeable, high energy density electrochemical cells containing an intercalation cathode, a metal anode, and an electrolyte of the above-described type are also disclosed.

Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, or treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use hydroxy and ether-containing oxyalkylene esters.

Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use tricarboxylic acid substituted oxyalkyl esters.

Abstract: This invention relates to nitrogen-containing oxyalkylene diester compositions for treating disease conditions including cancer and other proliferative diseases. The nitrogen-containing oxyalkylene diesters are represented by the formula ##STR1## where the nitrogen-containing group is R.sub.3 and includes particular alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl or heteroaryl groups, which have nitrogen-containing substituents, such as amines, amides, or nitrogen heteroatoms.

Abstract: A process for the preparation of a microsphere comprising a coating composed of one or more silica nanoparticles layers, comprises the steps of: a) providing a microsphere of polymeric material, the said microsphere having adsorbed on its surface one or more surfactants; and b) causing a layer of silica nanoparticles to coat the surface of the said microsphere by means of seeded polymerization of alkyl silicates onto the surface of said microsphere.

Abstract: A method and converter topology for ensuring charge and discharge of electric current to a coil so as to allow simultaneous and independent charge and discharge thereof, particularly suitable for a superconducting coil and showing an increase in power transfer by a factor of up to two as compared with prior art converters.

Abstract: This invention relates to the novel retinoyloxy(aryl-substituted)-alkylene butyrate compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of inhibiting histone deacetylase, ameliorating wrinkles, treating or ameliorating dermatological disorders, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.

Abstract: This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of ameliorating wrinkles, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.

Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dedendent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, or treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use hydroxy and ether-containing oxyalkylene esters.

Abstract: This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of ameliorating wrinkles, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.

Abstract: A method of diagnosing and determining the disease stage of a degenerative disease of the central nervous system associated with the impairment of integrative brain function is disclosed. The method includes the steps of (a) measuring a cytokine production level of peripheral mononuclear cells from a peripheral blood sample and (b) determining the disease stage by comparing the level determined in step (a) with a level generated by age-matched normal controls.

Abstract: Polymers containing a plurality of free hydroxy groups, such as cellulose, agarose or polyvinyl alcohol, are contacted in absence of reactants for hydroxy groups, with at least one N-heterocyclic compound, e.g. pyridine, pyrrole, pyridazine, their partially or fully hydrogenated analogs and any of these which may be substituted, in a pre-activation step prior to reaction with reactant for free hydroxy groups in the polymer, the polymer-bound residue of which reactant may be thereafter reacted in turn with amino compounds containing at least one unsubstituted N-attached hydrogen atom, e.g. proteins, thereby to form amine-polymer conjugates. The invention further relates to a powder, bandage, patch or like cover for application to wounds which has been manufactured from polymer containing a plurality of hydroxy groups by a process which includes the step of providing an amine conjugated to the polymer; the amine may be, e.g., trypsin, chymotrypsin, lysozyme, collagenase, albumin and hyaluronidase.

Abstract: This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof.

Abstract: A composition of matter includes a solid substrate having covalent bonds, provided by a connecting ligand, to at least one of (a) and (b), namely: (a) a single layer of at least one species of microspheres containing residual reactive functions; (b) a multiplicity of layers of at least one species of microspheres, wherein adjoining layers of multiplicity of layers are covalently linked together, the innermost layer of the multiplicity of layers having the covalent bonds to the solid substrate connected thereto, while at least the outermost layer of the multiplicity of layers contains residual reactive functions; the species of microspheres being selected from microspheres of silica, polyacrylic acid, polyglutaraldehyde, polyacrolein, poly(chloromethylated styrene) and albumin. At least some of the residual reactive functions may be used to immobilize drugs, prodrugs, proteins, biological cells and other controllably releasable substances.

Abstract: A nutritional composition, adapted for consumption by mammals, contains (1) an orally ingestible diluent or carrier, except an oily carrier or diluent which comprises C.sub.8-18 saturated fatty acids, oleic acid and derivatives of these acids, and (2) a composition of matter which consists of (a) from about 13.0 to about 27.5% by weight of at least one compound selected from linolenic acid and its salts, esters and amides, calculated as the free acid, and (b) about 87.0 to about 72.5% by weight of at least one compound selected from linoleic acid and its salts, esters and amides thereof, calculated as the free acid, the salts, esters and amides of linolenic and linoleic acid being both physiologically hydrolyzable and pharmacologically acceptable. The invention also relates to a method for treating a mammal for the purpose of inducing therein at least one physiological effect selected from memory enhancement and analgesia, by administration of an effective amount of the nutritional composition.

Abstract: This invention relates to novel methods of increasing the level of fetal hemoglobin (HbF) in a subject and methods of treating, preventing or ameliorating .beta.-globin or other HbF-related disorders by increasing the level of HbF in a subject in need of such treatment comprising administering one or more compounds of the Formulae (I), (II), or (III):(I) XCH.sub.2 --CHX--CHX--C(.dbd.O)--O--Z(II) CH.sub.3 --CO--CH.sub.2 --C(.dbd.O)--O--Z(III) CH.sub.3 --CH.sub.2 --CO--C(.dbd.O)--O--Zwherein:X is H, or one of X only may be OH;Z is --CHR--O--C(.dbd.O)R', --CHR--O--C(.dbd.